Cargando…

Prevalence of overuse of short-acting beta-2 agonists (SABA) and associated factors among patients with asthma in Germany

BACKGROUND: Overuse of short-acting beta-2 agonists (SABA), which do not treat the underlying inflammation of asthma, is linked to poor clinical outcomes such as increased exacerbation risk. This study, as part of the SABINA program, estimated the prevalence of SABA overuse and associated variables...

Descripción completa

Detalles Bibliográficos
Autores principales:	Worth, Heinrich, Criée, Carl-Peter, Vogelmeier, Claus F., Kardos, Peter, Becker, Eva-Maria, Kostev, Karel, Mokros, Ingo, Schneider, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051057/ https://www.ncbi.nlm.nih.gov/pubmed/33863317 http://dx.doi.org/10.1186/s12931-021-01701-3

Ejemplares similares

The Prospective Non-Interventional DACCORD Study in the National COPD Registry in Germany: design and methods
por: Kardos, Peter, et al.
Publicado: (2015)

Overuse of Short-Acting Beta-2 Agonists (SABAs) in Elite Athletes: Hypotheses to Explain It
por: Vertadier, Nicolas, et al.
Publicado: (2022)

Clinical Consequences of the Overuse of Short-Acting β2-Adrenergic Agonists (SABA) in the Treatment of Asthma in Spain: The SABINA Study
por: Molina, Jesús, et al.
Publicado: (2023)

COPD Assessment Test Changes from Baseline Correlate with COPD Exacerbations: A Longitudinal Analysis of the DACCORD Observational Study
por: Kardos, Peter, et al.
Publicado: (2020)

Impact of switching from triple therapy to dual bronchodilation in COPD: the DACCORD ‘real world’ study
por: Vogelmeier, Claus F., et al.
Publicado: (2022)

In ‘real world’ patients with COPD, exacerbation history, and not blood eosinophils, is the most reliable predictor of future exacerbations
por: Worth, Heinrich, et al.
Publicado: (2023)

Manifesto on the overuse of SABA in the management of asthma: new approaches and new strategies
por: Canonica, Giorgio Walter, et al.
Publicado: (2021)

“Real-life” inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD
por: Vogelmeier, Claus, et al.
Publicado: (2017)

A year in the life of German patients with COPD: the DACCORD observational study
por: Buhl, Roland, et al.
Publicado: (2016)

SABA Overuse in Russia – Burden and Possible Causes: An Analysis of the Russian Population in the SABINA III (SABA use IN Asthma) Study
por: Avdeev, Sergey, et al.
Publicado: (2022)

Dual bronchodilation vs triple therapy in the “real-life” COPD DACCORD study
por: Buhl, Roland, et al.
Publicado: (2018)

Health status in patients with COPD treated with roflumilast: two large noninterventional real-life studies: DINO and DACOTA
por: Kardos, Peter, et al.
Publicado: (2018)

Evaluation of short-acting Beta-2-agonist prescriptions and associated clinical outcomes: Findings from the SABA use IN Asthma (SABINA) study in Asia
por: Wang, Hao-Chien, et al.
Publicado: (2023)

Clarifying SABA overuse: Translating Canadian Thoracic Society guidelines into clinical practice
por: Ellis, Anne K., et al.
Publicado: (2022)

The prevalence and outcome of short-acting β2-agonists overuse in asthma patients in Taiwan
por: Wang, Cheng-Yi, et al.
Publicado: (2021)

Retrospective assessment of a collaborative digital asthma program for Medicaid-enrolled children in southwest Detroit: reductions in short-acting beta-agonist (SABA) medication use
por: Barrett, Meredith, et al.
Publicado: (2023)

Short-acting β2-agonists (SABA) bronchodilator sales and outdoor mould in central France
por: Caillaud, D. M., et al.
Publicado: (2019)

Uncovering the Burden of Rhinitis in Patients Purchasing Nonprescription Short-Acting β-Agonist (SABA) in the Community
por: Alamyar, Sara, et al.
Publicado: (2023)

What patients really think about asthma guidelines: barriers to guideline implementation from the patients’ perspective
por: Lingner, H., et al.
Publicado: (2017)

Asthma and COVID-19: In Defense of Evidence-Based SABA
por: Amirav, Israel, et al.
Publicado: (2020)

Characteristics of patients with asthma overprescribed short-acting beta-agonist (SABA) reliever inhalers stratified by blood eosinophil count in North East London: a cross-sectional observational study
por: Pfeffer, Paul, et al.
Publicado: (2023)

SABINA: An Overview of Short-Acting β(2)-Agonist Use in Asthma in European Countries
por: Janson, Christer, et al.
Publicado: (2020)

Effective Asthma Management: Is It Time to Let the AIR out of SABA?
por: Kaplan, Alan, et al.
Publicado: (2020)

The Changing Asthma Management Landscape and Need for Appropriate SABA Prescription
por: Domingo, Christian, et al.
Publicado: (2023)

SABAs as Reliever Medications in Asthma Management: Evidence-Based Science
por: Amirav, Israel, et al.
Publicado: (2023)

A retrospective database study comparing treatment outcomes and cost associated with choice of fixed-dose inhaled corticosteroid/long-acting β(2)-agonists for asthma maintenance treatment in Germany
por: Aballéa, S, et al.
Publicado: (2008)

Reducing Tolerance for SABA and OCS towards the Extreme Ends of Asthma Severity
por: Bakakos, Petros, et al.
Publicado: (2022)

High Use of SABAs is Associated with Higher Exacerbation Rate in Dutch Patients with Asthma
por: Baron, Anna Jetske, et al.
Publicado: (2021)

Safety of SABA Monotherapy in Asthma Management: a Systematic Review and Meta-analysis
por: Sriprasart, Thitiwat, et al.
Publicado: (2022)

Psychometric properties of the Spanish SABA Reliance Questionnaire (SRQ) among patients with asthma
por: Martínez, Mar, et al.
Publicado: (2023)

La reina de Saba
por: Mardrus, Joseph Charles, 1868-1949
Publicado: (1992)

Saba silhouettes : life stories from a Caribbean Island /
Publicado: (1987)

SABA use as an indicator for asthma exacerbation risk: an observational cohort study (SABINA Canada)
por: Noorduyn, Stephen G., et al.
Publicado: (2022)

Overuse of short-acting β(2)-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme
por: Nwaru, Bright I., et al.
Publicado: (2020)

Beta-agonist overuse and delay in obtaining medical review in high risk asthma: a secondary analysis of data from a randomised controlled trial
por: Pilcher, Janine, et al.
Publicado: (2017)

Clinical and Patient-Related Variables Associated with Initiating GLP-1 Receptor Agonist Therapy in Type 2 Diabetes Patients in Primary Care in Germany
por: Qiao, Qing, et al.
Publicado: (2016)

Understanding reliever overuse in patients purchasing over-the-counter short-acting beta(2) agonists: an Australian community pharmacy-based survey
por: Azzi, Elizabeth A, et al.
Publicado: (2019)

Die Königin von Saba ; und andere Novellen /
por: Hamsun, Knut, 1859-1952
Publicado: (1899)

Asthma-related hospitalizations after implementing SABA-free asthma management with a maintenance and anti-inflammatory reliever regimen
por: Nannini, L. J., et al.
Publicado: (2022)

Gonadotropin-releasing Hormone Agonist Overuse: Urologists’ Response to Reimbursement and Characteristics Associated with Persistent Overuse
por: Ellis, Shellie D., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_uifgfveqntp4rghdct2r53dka0